Implementation of the Community Network of Reference Laboratories for Human Influenza in Europe

Instituto de Salud Carlos III, Madrid, Madrid, Spain
Journal of Clinical Virology (Impact Factor: 3.02). 11/2005; 34(2):87-96. DOI: 10.1016/j.jcv.2005.02.005
Source: PubMed


The increased need for accurate influenza laboratory surveillance data in the European Union required formalisation of the existing network of collaborating national influenza reference laboratories participating in the European Influenza Surveillance Scheme (EISS).
To establish a Community Network of Reference Laboratories for Human Influenza in Europe (CNRL).
Virologists in EISS defined the objective and tasks of the CNRL. Performance of the laboratories in the tasks was monitored by questionnaire-based inventories and quality control assessments (QCA). Subsequently, actions were defined to improve the performance of the CNRL.
The CNRL started in April 2003 and included as of May 2004 32 laboratories in 24 European countries. The objective is to provide high quality reference services for human influenza surveillance, early warning and pandemic preparedness in Europe. The defined basic tasks are direct detection, culture, typing, subtyping and strain characterisation of influenza virus, diagnostic influenza serology and storage of clinical specimens and virus isolates. The questionnaire-based inventories and QCAs revealed that the majority of CNRL laboratories perform well in most of the basic tasks, although improvements are needed in certain areas of virus testing. Therefore, task groups have been established to further improve the methods used in the network. The CNRL has proven its usefulness during the 2003-2004 season by the reporting of accurate data concerning the flu epidemic caused by A/Fujian/411/2002 (H3N2)-like viruses and by the rapid sharing of information, protocols and reagents during the A(H5N1) and A(H7N3) epizootics in Asia and Canada.
EISS has established a functioning Community Network of Reference Laboratories for Human Influenza in Europe and laid the foundation for further enhancement and collaborations. Important next steps include improving the laboratories to carry out all basic tasks and collaboration with the European Centre for Disease Prevention and Control.

Download full-text


Available from: Koos van der Velden, Jul 14, 2014
  • Source

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the important outcomes of the recently held meeting of the World Heatlh Organization (EHO), the Food and Agriculture Organization (FAO) of the United Nations, the World Organization of Animal Heath (OIE) and the World Bank in Genevan NOvember 7- 9, 2005, on the threat of avian inluenza A(H5N1), was that there is still a window of opporntunity ot minimize teh threat to both the animal and human populations at the source (the birds) through rapied reduction of the viraal burgen of A(H5N1) influenca . Thorouth the application of advanced biotecnology diagnostic tools for early detection, it is hoped that mass culling of poultry an human losses can be minmize, It was stressed that surveillance by veteranary and human health services should be strengthend to allow early detection, timely notification and rapid medhanisms for an effective response.
    Expert Review of Molecular Diagnostics 02/2006; 6(1):1-4. DOI:10.1586/14737159.6.1.1 · 3.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The 2004-2005 influenza season in Europe started in late December 2004 and the first influenza activity occurred in the west and southwest (Spain, United Kingdom and Ireland). Influenza activity then moved gradually east across Europe during January and early February 2005, and from late February until late March, most movement was south to north. The intensity of clinical influenza activity in ten out of 23 countries was higher than during the 2003-2004 season, and lower or equal to the 2003-2004 season in the other 13 countries. The highest consultation rates were generally observed among children aged 0-14 years. However, the peak consultation rates due to influenza-like illness or acute respiratory infection were not especially high when compared with historical data. The predominant virus strain was influenza A (83% of total detections) of the H3 subtype (85% of H-subtyped A viruses), with fewer influenza B (17% of total detections) or A(H1) viruses (15 % of H-subtyped A viruses) detected. The vast majority of A(H3) viruses were similar to the reference strains A/Wellington/1/2004 (H3N2) and, subsequently, A/California/7/2004 (H3N2) that are closely related drift variants of the A/Fujian/411/2002 (H3N2) prototype vaccine strain. The B viruses co-circulated with A viruses during the whole influenza season in 11 out of 24 countries. Seven of these were located in the northeast of Europe and in these countries the proportion of B viruses was higher (range: 31-60%) than in the rest of Europe (range: 6-26%). In 13 out of 24 countries the B viruses circulated relatively late in the season. About 43% of all antigenically characterised B viruses were B/Hong Kong/330/2001-like (B/Victoria/2/87 lineage), a strain that is distinguishable from the vaccine influenza B strain, which was a B/Yamagata/16/88 lineage virus. Based on the viruses detected worldwide until February 2005, the World Health Organization modified the composition of the 2005-2006 influenza vaccine from the 2004-2005 season vaccine to include a new A(H3N2) component: an A/California/7/2004 (H3N2)-like virus.
    Eurosurveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 02/2006; 11(5):111-8. · 5.72 Impact Factor
Show more